US FDA approves Prism's first product, Nexterone
This article was originally published in Scrip
Prism Pharmaceuticals' first product, Nexterone, a new formulation of the anti-arrhythmic, amiodarone, has been approved for marketing in the US. It is also the first product using CyDex Pharmaceuticals' Captisol technology to be approved there.
You may also be interested in...
Germany’s family-controlled big pharma, Merck KGaA, is divesting its allergens business, Allergopharma to the fast-growing Munich healthcare company, Dermapharm Holding.
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Sweden’s mid-sized pharmaceutical company, Swedish Orphan Biovitrum, has expanded into hematology and strengthened its immunology business, growing its top and bottom lines in 2019.